WE CREATE VALUE THROUGH OPEN INNOVATION.
The sharing of knowledge and skills is one of the key values that motivate and inspire Kedrion’s daily activities within the communities in which it operates.
We want to seize the opportunities offered by the exhange of ideas and encounters with the academic-scientific community, patients, the world of industry and, in particular, with start-ups, driven by the ultimate goal of continuing to provide innovative and effective therapies designed to meet the needs and expectations of patients around the world.
Synergy and the continuous exchange of ideas and experiences are the key principles of our strategic path for open innovation.
Guided by this vision, year after year, we have continued to support medical-scientific research initiatives and projects aimed at technological innovation. For example, in Italy, we collaborate with important academic experts and biotech companies in fields such as hepatology, regenerative medicine, neuroscience and immunology, including:
- The University of Pisa
- The University of Siena
- Vita-Salute San Raffaele University of Milan
- IMT School for Advanced Studies Lucca
- National Research Council (CNR) – Pisa Research Area
- TLS Foundation, Toscana Life Sciences
- Tuscany Region
More specifically, in 2019, we decided to extend and consolidate our local presence in the field of training and innovation by initiating a strategic path for open innovation, which in its first phase, mainly addressed the world of start-ups and the academic-scientific community in the Life Sciences industry, with the aim of evaluating new project proposals, identifying which of these proposals can benefit from interaction with Kedrion, thus accelerating progress and creating value for the community and for patients.
Kedrion’s Research and Innovation team structures its offers flexibly in order to adapt the company’s collaboration to the specific needs of each partner. Types of agreements include in-licensing, out-licensing/risk-sharing, in-kind collaboration, research collaborations, options, equity investments and acquisitions.
By taking an open approach to innovation and drug discovery, we are focusing on new technologies for the next generation of hematology therapies. We are also interested in opportunities in immunology, hepatology, peripheral nervous system treatments and regenerative medicine.
We are building success together. We are looking for collaborations that:
- Support scientific discoveries in academic laboratories that focus on research in Kedrion’s areas of interest, with the clear objective of filling an unresolved medical need in the therapeutic or diagnostic fields;
- Represent a clear innovation by exploiting new biological knowledge, new applications of existing solutions, and/or new ways of administrating drug development in subject areas which are of interest to the company.
We offer collaboration at different levels, from the generation of ideas to proof of concept, focusing in particular on innovative proposals concerning the preclinical validation of new therapeutic and diagnostic approaches in the following areas:
- Hematology (in particular, non-oncological diseases)
- Immunology (for example, immunodeficiencies)
- Regenerative medicine (for example, wound healing)
- Hepatology (in particular, non-oncological diseases)
- Fetal and maternal health
- Critical care
30.07.2019 – PoC call for tenders by the University of Pisa: Kedrion finances an innovative project for the treatment of Hemophilia A
INFOREC – Engineering and production of recombinant Factor VIII with long half-life and high coagulation activity – is the winning project of the “Proof of Concept” (PoC) call for tenders, launched by the University of Pisa in collaboration with Kedrion in order to finance the development of advanced technologies, starting from an innovative idea, producing a working prototype and then transfering this new technology to companies or to the market.
Selected among thirteen innovative ideas presented by the University of Pisa’s Life Sciences research teams, the INFOREC biotechnology project “has the potential to pave the way for important developments in both replacement therapy and gene therapy for people affected by Hemophilia A, leading to a significant improvement in their care,” as explained in the margins of the announcement by Prof. Alessandro Gringeri, Chief Medical and R&D Officer at Kedrion.
Kedrion will support the project – which will last up to one year – with an initial investment of 15 thousand euros.
Read the news: here.
18.06.2019 – Kedrion meets with “made in Tuscany” technological research projects
Kedrion was featured in a Partnering Day, a series of meetings promoted by the Region of Tuscany through Invest in Tuscany to connect large companies involved in technological research projects and start-ups in Tuscany.
With the support of Invest in Tuscany and the collaboration of Local Global and the Toscana Life Sciences Foundation, Kedrion selected 12 potential partners, who had the opportunity to present their innovative projects in areas such as nanotechnology, bioengineering and biorobotics during a day-long event dedicated to this purpose. Many therapeutic areas were involved, including immunology, allergology, neurology, hematology and rare diseases.
Read the news: here.
06.06.2019 – Kedrion among Unicredit Start Lab committee members
Prof. Alessandro Gringeri, Chief Medical and R&D Officer at Kedrion, is a part of the Committee for UniCredit Start Lab 2019, the Open Innovation platform launched six years ago by Unicredit with the aim of identifying and supporting the most advanced start-ups in various business sectors. As a member of the committee called to evaluate the projects presented in the Life Sciences field, Prof. Gringeri had the opportunity to learn about the ideas of young innovative entrepreneurs and to explore new opportunities for collaboration.